Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101

Pediatric Blood and Cancer

Volumn 63, Issue 8, 2016, Pages 1468-1470

  Nagasubramanian, Ramamoorthy ^a   Wei, Julie ^a   Gordon, Paul ^a   Rastatter, Jeff C ^b   Cox, Michael C ^c   Pappo, Alberto ^d  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Loxo Oncology Inc   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ETV6 NTRK3; gene fusion; infantile fibrosarcoma; LOXO 101; tropomyosin related kinase (TRK)

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; N [5 [2 (2,5 DIFLUOROPHENYL) 1 PYRROLIDINYL]PYRAZOLO[1,5 A]PYRIMIDIN 3 YL] 3 HYDROXY 1 PYRROLIDINECARBOXAMIDE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; CYTOREDUCTIVE SURGERY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FUSION; HEMANGIOMATOSIS; HUMAN; INFANT; INFANT DISEASE; INFANTILE FIBROSARCOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NECK TUMOR; NTRK3 ETV6 FUSION GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TRACHEOSTOMY; TREATMENT OUTCOME;

EID: 85027921757     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26026     Document Type: Article

References (21)

1. Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer 1976;38:729–739.
2. Loh ML, Ahn P, Perez-Atayde AR, Gebhardt MC, Shamberger RC, Grier HE. Treatment of infantile fibrosarcoma with chemotherapy and surgery: Results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. J Pediatr Hematol Oncol 2002;24:722–726.
3. Orbach D, Brennan B, De Paoli A, Gallego S, Mudry P, Francotte N, van Noesel M, Kelsey A, Alaggio R, Ranchere D, De Salvo GL, Casanova M, Bergeron C, Merks JH, Jenney M, Stevens MC, Bisogno G, Ferrari A. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience. Eur J Cancer 2016;57:1–9.
4. Orbach D, Rey A, Cecchetto G, Oberlin O, Casanova M, Thebaud E, Scopinaro M, Bisogno G, Carli M, Ferrari A. Infantile fibrosarcoma: Management based on the European experience. J Clin Oncol 2010;28:318–323.
5. Lannon CL, Sorensen PH. ETV6-NTRK3: A chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol 2005;15:215–223.
6. Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 2015;5:1049–1057.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
8. Weinstein IB. Cancer. Addiction to oncogenes—The Achilles heal of cancer. Science 2002;297:63–64.
9. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13:772–787.
10. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184–187.
11. Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998;58:5046–5048.
12. Makretsov N, He M, Hayes M, Chia S, Horsman DE, Sorensen PHB, Huntsman DG. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004;40:152–157.
13. Rubin JB, Segal RA. Growth, survival and migration: The Trk to cancer. Cancer Treat Res 2003;115:1–18.
14. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J, Easton J, Edmonson M, Ma X, Lu C, Nagahawatte P, Hedlund E, Rusch M, Pounds S, Lin T, Onar-Thomas A, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46:444–450.
15. Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016;122:1097–1107.
16. Wu G, Barnhill RL, Lee S, Li Y, Shao Y, Easton J, Dalton J, Zhang J, Pappo A, Bahrami A. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Mod Pathol 2016;29:359–369.
17. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371:1005–1015.
18. Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol 2016. doi: 10.1001/jamaoncol.2015.5689.
19. Haller F, Knopf J, Ackermann A, Bieg M, Kleinheinz K, Schlesner M, Moskalev EA, Will R, Satir AA, Abdelmagid IE, Giedl J, Carbon R, Rompel O, Hartmann A, Wiemann S, Metzler M, Agaimy A. Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: A subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol 2016;238:700–710.
20. Wong V, Pavlick D, Brennan T, Yelensky R, Crawford J, Ross JS, Miller VA, Malicki D, Stephens PJ, Ali SM, Ahn H. Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to Crizotinib. J Natl Cancer Inst 2016;108:djv307. doi: 10.1093/jnci/djv307
21. Hong DS, Brose MS, Doebele RC, Shaw AT, Dowlati A, Bauer TM, Farago AF, Estrada-Bernal A, Lee AT, Cox MC, Nanda N, Low JA, Burris HA. Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Mol Cancer Ther 2015;14(12 Suppl 2):PR13.